Frontage, a global CRO based in Ecton, Penn., has signed an agreement to develop clinical trial supplies with AtheroNova, a biotech company focused on R&D of compounds to regress atherosclerotic plaque.

Frontage will commence work on the analysis, formulation, compounding and tabletization of the company's AHRO-001 tablets in advance of the upcoming phase I human clinical studies.

"Frontage has been extremely diligent in dealing with the technical and physical requirements of our AHRO-001 compound and we look forward to commencing our project in the coming days," said Thomas W. Gardner, CEO of AtheroNova. "We are very confident that Frontage will deliver a quality product in a timely manner. We continue to adhere to our vigorous development path and anticipate additional exciting development milestones in the coming months."

Balbir Brar, senior vice president of drug development, AtheroNova, added, "Our utmost confidence stems from previous projects I have worked on with Frontage and have always found their people, facilities and product quality to be some of the best in the industry."